J Vet Sci.  2014 Dec;15(4):569-574. 10.4142/jvs.2014.15.4.569.

Efficacy of an oral hyaluronate and collagen supplement as a preventive treatment of elbow dysplasia

• Marti-Angulo S
• Garcia-Lopez N
• Diaz-Ramos A

• KMID: 2070245
• DOI: http://doi.org/10.4142/jvs.2014.15.4.569

Abstract

One hundred and five Labrador dogs were randomly divided into two groups to determine the number of animals that develop elbow dysplasia when treated with an oral supplement compared to untreated ones. Efficacy of the oral treatment was also evaluated once illness was diagnosed. The supplement (Hyaloral) contained hyaluronic acid, hydrolysed collagen, glucosamine, chondroitin sulphate, and gamma oryzanol. Clinical evaluation of the elbow joints was completed at months 3, 6, 12, and 20 by orthopaedic evaluations, radiography, serologic and blood analysis, and veterinarian evaluation of dysplasia symptoms. All side effects were recorded. In the control group, 33.3% of the dogs developed radiographic evidence of elbow dysplasia compared to 18.5% in the treated group. Symptoms of dysplasia at 12 months differed between the treated (12.5%) and control (61.5%) animals, and were significantly different at 20 months (p < 0.05). Differences in lameness along with movement and swelling of the elbows between groups were observed after 12 months. The treated group had improved significantly by the last visit (p < 0.05). No adverse side effects were reported. In conclusion, oral treatment with Hyaloral may have a potential cumulative action that provides protection against dysplasia and significantly improves symptoms of elbow dysplasia.

Keyword

canine; chondroprotector; collagen; elbow dysplasia; hyaluronate

MeSH Terms

Administration, Oral
Animals
Collagen/*therapeutic use
Dietary Supplements/analysis
Dog Diseases/*prevention & control
Dogs
Drug Combinations
Elbow Joint/*abnormalities
Genetic Diseases, Inborn/prevention & control/*veterinary
Hyaluronic Acid/*therapeutic use
Joint Diseases/prevention & control/*veterinary
Spain
Species Specificity
Collagen
Drug Combinations
Hyaluronic Acid

Figure

• 

  Fig. 1 Percentage of dogs with symptoms of dysplasia at 12 (third visit) and 20 (forth visit) months of age in the control (untreated) and Hyaloral-treated groups.

Reference

1. Altman RD, Dean DD, Muniz OE, Howell DS. Prophylactic treatment of canine osteoarthritis with glycosaminoglycan polysulfuric acid ester. Arthritis Rheum. 1989; 32:759–766.

2. Aragon CL, Hofmeister EH, Budsberg SC. Systematic review of clinical trials of treatments for osteoarthritis in dogs. J Am Vet Med Assoc. 2007; 230:514–521.

3. Bouck GR, Miller CW, Taves CL. A comparison of surgical and medical treatment of fragmented coronoid process and osteochondritis dissecans of the canine elbow. Vet Comp Orthop Traumatol. 1995; 8:177–183.

4. Carmona JU, Argüelles D, Deulofeu R, Martínez-Puig D, Prades M. Effect of the administration of an oral hyaluronan formulation on clinical and biochemical parameters in young horses with osteochondrosis. Vet Comp Orthop Traumatol. 2009; 22:455–459.

5. Carreno MR, Muniz OE, Howell DS. The effect of glycosaminoglycan polysulfuric acid ester on articular cartilage in experimental osteoarthritis: effects on morphological variables of disease severity. J Rheumatol. 1986; 13:490–497.

6. Cook CR, Cook JL. Diagnostic imaging of canine elbow dysplasia: a review. Vet Surg. 2009; 38:144–153.

7. de Haan JJ, Goring RL, Beale BS. Evaluation of polysulfated glycosaminoglycan for the treatment of hip dysplasia in dogs. Vet Surg. 1994; 23:177–181.

8. Durante EJ, Brusa MC. Aspects of elbow dysplasia in dogs. Analecta Veterinaria. 1998; 18:59–70.

9. Ginja MMD, Silvestre AM, Gonzalo-Orden JM, Ferreira AJA. Diagnosis, genetic control and preventive management of canine hip dysplasia: a review. Vet J. 2010; 184:269–276.

10. Innes J. Getting the elbow: diagnosis and management of elbow disease in dogs. J Small Anim Pract. 2009; 50:18–20.

11. Kirberger RM, Fourie SL. Elbow dysplasia in the dog: pathophysiology, diagnosis and control. J S Afr Vet Assoc. 1998; 69:43–54.

12. Kirberger RM, Stander N. Incidence of canine elbow dysplasia in South Africa. J S Afr Vet Assoc. 2007; 78:59–62.

13. Kirkby KA, Lewis DD. Canine hip dysplasia: reviewing the evidence for nonsurgical management. Vet Surg. 2012; 41:2–9.

14. Lust G, Williams AJ, Burton-Wurster N, Beck KA, Rubin G. Effects of intramuscular administration of glycosaminoglycan polysulfates on signs of incipient hip dysplasia in growing pups. Am J Vet Res. 1992; 53:1836–1843.

15. Mäki K, Janss LLG, Groen AF, Liinamo AE, Ojala M. An indication of major genes affecting hip and elbow dysplasia in four Finnish dog populations. Heredity (Edinb). 2004; 92:402–408.

16. Michelsen J. Canine elbow dysplasia: aetiopathogenesis and current treatment recommendations. Vet J. 2013; 196:12–19.

17. Samoy Y, Van Ryssen B, Gielen I, Walschot N, van Bree H. Review of the literature: elbow incongruity in the dog. Vet Comp Orthop Traumatol. 2006; 19:1–8.

18. Woolliams JA, Lewis TW, Blott SC. Canine hip and elbow dysplasia in UK Labrador retrievers. Vet J. 2011; 189:169–176.

19. Bottegoni C, Muzzarelli RAA, Giovannini F, Busilacchi A, Gigante A. Oral chondroprotection with nutraceuticals made of chondroitin sulphate plus glucosamine sulphate in osteoarthritis. Carbohydr Polym. 2014; 109:126–138.